RGNX

REGENXBIO Inc. NASDAQ

Healthcare ·Biotechnology ·US · regenxbio.com

$9.39

Mkt Cap $484.7M

52w Low $6.89 26.9% of range 52w High $16.19

50d MA $8.76 200d MA $10.53

P/E (TTM) -2.4x

EV/EBITDA -6.7x

P/B 4.6x

Debt/Equity 2.5x

ROE -188.7%

P/FCF -5.9x

RSI (14) —

ATR (14) —

Beta 1.13

50d MA $8.76

200d MA $10.53

Avg Volume 833.4K

About

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. T…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	-1.01	-1.30	-28.7%	8.72	-3.0%	-0.8%	+19.0%	+13.5%	+7.6%	+4.1%	—
Nov 6, 2025	AMC	-1.38	-1.20	+13.0%	11.17	-1.5%	+0.4%	-1.3%	+3.4%	+3.8%	+4.2%	—
Aug 7, 2025	AMC	-1.13	-1.38	-22.1%	7.90	-1.0%	-0.6%	-5.6%	+2.5%	+13.0%	+14.7%	—
May 12, 2025	AMC	0.41	0.12	-70.7%	7.97	+0.0%	+2.6%	+4.5%	+8.4%	+11.5%	+22.8%	—
Mar 13, 2025	AMC	-1.27	-1.01	+20.5%	6.55	+7.9%	+2.6%	+6.9%	+19.1%	+29.8%	+27.6%	—
Nov 6, 2024	AMC	-1.16	-1.17	-0.9%	9.43	+8.2%	+18.7%	+18.3%	+22.6%	+11.2%	+13.1%	—
Aug 1, 2024	AMC	-1.29	-1.05	+18.6%	13.31	-7.4%	-2.0%	-6.0%	-4.7%	-9.5%	-10.7%	—
May 8, 2024	AMC	-1.28	-1.38	-7.8%	16.67	-0.7%	-5.9%	-7.4%	-5.6%	-5.2%	-2.6%	—
Feb 27, 2024	AMC	-1.27	-1.43	-12.6%	20.02	-5.0%	-0.6%	-12.9%	+5.8%	+6.7%	+22.9%	—
Nov 8, 2023	AMC	-1.44	-1.41	+2.1%	16.41	+3.8%	+2.4%	+8.7%	+8.1%	+16.1%	+16.6%	—
Aug 2, 2023	AMC	-1.26	-1.66	-31.7%	18.90	-7.2%	-7.5%	-6.3%	-7.1%	-5.6%	-4.2%	—
May 3, 2023	AMC	-1.52	-1.53	-0.7%	20.23	-11.0%	-1.6%	-6.7%	-8.8%	-7.5%	-4.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.65	$9.75	+12.7%	+20.0%	+14.5%	+8.4%	+5.0%	-0.9%
Mar 6	Morgan Stanley	Maintains	Overweight → Overweight	—	$8.72	$8.46	-3.0%	-0.8%	+19.0%	+13.5%	+7.6%	+4.1%
Feb 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$10.31	$9.02	-12.5%	-14.2%	-17.6%	-19.0%	-22.5%	-22.0%
Feb 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.31	$9.02	-12.5%	-14.2%	-17.6%	-19.0%	-22.5%	-22.0%
Feb 10	Chardan Capital	Maintains	Buy → Buy	—	$10.31	$9.02	-12.5%	-14.2%	-17.6%	-19.0%	-22.5%	-22.0%
Feb 10	Goldman Sachs	Maintains	Neutral → Neutral	—	$10.31	$9.02	-12.5%	-14.2%	-17.6%	-19.0%	-22.5%	-22.0%
Jan 29	Chardan Capital	Maintains	Buy → Buy	—	$11.01	$10.81	-1.8%	+5.4%	+1.4%	-2.1%	-1.4%	-2.4%
Dec 19	Stifel	Maintains	Buy → Buy	—	$13.51	$13.79	+2.1%	+8.0%	+10.8%	+6.2%	+7.0%	+4.8%
Dec 15	Leerink Partners	Maintains	Outperform → Outperform	—	$13.87	$14.37	+3.6%	-0.3%	+1.7%	-5.0%	-2.6%	+5.2%
Nov 20	Chardan Capital	Maintains	Buy → Buy	—	$10.93	$11.18	+2.3%	-0.5%	+8.0%	+11.9%	+23.1%	+21.3%
Nov 7	RBC Capital	Maintains	Outperform → Outperform	—	$11.17	$11.00	-1.5%	+0.4%	-1.3%	+3.4%	+3.8%	+4.2%
Oct 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.69	$10.73	+0.4%	-1.7%	+14.3%	+13.8%	+2.2%	+6.1%
Sep 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.71	$9.72	+0.1%	-2.4%	+1.9%	-1.4%	-2.3%	-5.3%
Sep 8	Chardan Capital	Maintains	Buy → Buy	—	$9.71	$9.72	+0.1%	-2.4%	+1.9%	-1.4%	-2.3%	-5.3%
Aug 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.71	$8.26	-5.2%	-7.8%	-7.3%	-6.9%	+3.4%	+3.0%
Aug 8	RBC Capital	Maintains	Outperform → Outperform	—	$7.90	$7.82	-1.0%	-0.6%	-5.6%	+2.5%	+13.0%	+14.7%
Aug 8	Barclays	Maintains	Overweight → Overweight	—	$7.90	$7.82	-1.0%	-0.6%	-5.6%	+2.5%	+13.0%	+14.7%
Aug 8	Chardan Capital	Maintains	Buy → Buy	—	$7.90	$7.82	-1.0%	-0.6%	-5.6%	+2.5%	+13.0%	+14.7%
Jun 9	Chardan Capital	Maintains	Buy → Buy	—	$9.61	$9.87	+2.7%	-0.8%	+2.1%	+6.1%	+6.1%	-3.5%
Apr 17	Goldman Sachs	Maintains	Neutral → Neutral	—	$6.16	$6.10	-1.0%	-3.6%	+8.3%	+26.9%	+44.0%	+49.4%
Mar 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.36	$8.22	-1.7%	-1.4%	+4.1%	-1.8%	-1.9%	-5.4%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.50	$8.37	-1.5%	-1.6%	-3.1%	+2.4%	-3.4%	-3.5%
Mar 20	Chardan Capital	Maintains	Buy → Buy	—	$8.50	$8.37	-1.5%	-1.6%	-3.1%	+2.4%	-3.4%	-3.5%
Mar 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.72	$6.71	-0.1%	+4.2%	+16.1%	+26.5%	+24.4%	+22.6%
Mar 14	Morgan Stanley	Maintains	Overweight → Overweight	—	$6.55	$7.07	+7.9%	+2.6%	+6.9%	+19.1%	+29.8%	+27.6%
Mar 14	Chardan Capital	Maintains	Buy → Buy	—	$6.55	$7.07	+7.9%	+2.6%	+6.9%	+19.1%	+29.8%	+27.6%
Feb 11	Goldman Sachs	Downgrade	Buy → Neutral	—	$7.89	$7.41	-6.1%	-7.1%	-8.7%	-7.2%	-7.5%	-3.9%
Jan 21	RBC Capital	Maintains	Outperform → Outperform	—	$7.37	$7.41	+0.5%	+2.7%	+6.5%	+7.9%	+6.9%	+4.1%
Jan 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.05	$7.40	+5.0%	+5.5%	+1.4%	+4.5%	+7.4%	+11.3%
Dec 11	RBC Capital	Maintains	Outperform → Outperform	—	$9.76	$9.75	-0.1%	-4.7%	-10.7%	-15.2%	-12.5%	-13.2%
Nov 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.63	$9.38	-2.6%	-4.7%	-0.4%	-0.5%	-0.8%	+3.9%
Nov 20	Chardan Capital	Maintains	Buy → Buy	—	$9.56	$9.56	+0.0%	+0.7%	-4.0%	+0.3%	+0.2%	-0.1%
Nov 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.43	$10.20	+8.2%	+18.7%	+18.3%	+22.6%	+11.2%	+13.1%
Oct 22	Chardan Capital	Maintains	Buy → Buy	—	$10.37	$10.27	-1.0%	-7.5%	-6.1%	-7.6%	-9.8%	-9.5%
Sep 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.34	$11.25	-0.8%	-0.5%	+0.4%	+1.2%	+0.5%	+4.0%
Aug 5	Barclays	Maintains	Overweight → Overweight	—	$13.04	$12.29	-5.8%	-4.1%	-2.7%	-7.7%	-8.8%	-10.4%
Aug 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.04	$12.29	-5.8%	-4.1%	-2.7%	-7.7%	-8.8%	-10.4%
Jun 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.21	$12.20	-0.1%	-2.7%	-1.6%	+4.8%	+0.9%	-5.7%
May 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.80	$16.28	+3.0%	+2.7%	+1.3%	+1.2%	+0.4%	-3.0%
Apr 12	Stifel	Maintains	Buy → Buy	—	$19.02	$19.02	+0.0%	-4.9%	-5.3%	-8.0%	-10.5%	-15.3%
Mar 8	RBC Capital	Upgrade	Sector Perform → Outperform	—	$23.23	$24.24	+4.3%	-2.1%	-1.6%	-5.4%	-3.3%	-5.9%
Mar 7	Barclays	Maintains	Overweight → Overweight	—	$24.00	$23.38	-2.6%	-3.2%	-5.2%	-4.8%	-8.4%	-6.4%
Mar 7	Chardan Capital	Maintains	Buy → Buy	—	$24.00	$23.38	-2.6%	-3.2%	-5.2%	-4.8%	-8.4%	-6.4%
Mar 6	Baird	Maintains	Outperform → Outperform	—	$24.61	$26.74	+8.7%	-2.5%	-5.6%	-7.6%	-7.2%	-10.7%
Mar 6	Leerink Partners	Upgrade	Market Perform → Outperform	—	$24.61	$26.74	+8.7%	-2.5%	-5.6%	-7.6%	-7.2%	-10.7%
Feb 28	Wedbush	Maintains	Neutral → Neutral	—	$20.02	$19.01	-5.0%	-0.6%	-12.9%	+5.8%	+6.7%	+22.9%
Feb 12	Wedbush	Maintains	Neutral → Neutral	—	$16.21	$16.29	+0.5%	+7.1%	-1.0%	+3.6%	+13.8%	+16.2%
Oct 5	Wedbush	Maintains	Neutral → Neutral	—	$15.16	$15.04	-0.8%	+4.4%	+4.8%	+6.0%	+10.9%	+10.9%
Oct 4	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$16.50	$16.84	+2.1%	-8.1%	-4.1%	-3.7%	-2.6%	+1.9%
Aug 29	Morgan Stanley	Maintains	Overweight → Overweight	—	$18.41	$18.41	+0.0%	-0.1%	+0.1%	-3.9%	-1.5%	-5.3%

Recent Filings

8-K · 1.01 !! High

Unknown — 8-K 1.01: Material Agreement

Regeneron's partnership with GlaxoSmithKline could accelerate commercial reach and reduce development costs, potentially boosting near-term revenue while validating pipeline strength.

Mar 20

8-K

REGENXBIO Inc. -- 8-K Filing

RegenXBio is advancing multiple late-stage gene therapy programs targeting rare and retinal diseases, with key clinical catalysts expected throughout 2026.

Mar 5

8-K · 8.01 !! High

REGENXBIO Inc. -- 8-K 8.01: Material Event / Announcement

RegenXBio received a Complete Response Letter from the FDA regarding its RGX-121 gene therapy for Mucopolysaccharidosis type II, delaying market approval and requiring additional clinical or manufacturing data.

Feb 10

Data updated apr 26, 2026 10:41pm · Source: massive.com